Header Logo

Connection

CHRISTIE BALLANTYNE to Triglycerides

Back to Details
This is a "connection" page, showing publications CHRISTIE BALLANTYNE has written about Triglycerides.
CHRISTIE BALLANTYNE
Connection Strength
8.729
Triglycerides
  1. Plozasiran (ARO-APOC3) for Severe Hypertriglyceridemia: The SHASTA-2 Randomized Clinical Trial. JAMA Cardiol. 2024 Jul 01; 9(7):620-630.
    View in: PubMed
    Score: 0.717
  2. Plozasiran, an RNA Interference Agent Targeting APOC3, for Mixed Hyperlipidemia. N Engl J Med. 2024 09 12; 391(10):899-912.
    View in: PubMed
    Score: 0.712
  3. Residual Cardiovascular Risk at Low LDL: Remnants, Lipoprotein(a), and Inflammation. Clin Chem. 2021 01 08; 67(1):143-153.
    View in: PubMed
    Score: 0.563
  4. Icosapent ethyl (eicosapentaenoic acid ethyl ester): Effects on remnant-like particle cholesterol from the MARINE and ANCHOR studies. Atherosclerosis. 2016 10; 253:81-87.
    View in: PubMed
    Score: 0.415
  5. Effects of icosapent ethyl on lipoprotein particle concentration and size in statin-treated patients with persistent high triglycerides (the ANCHOR Study). J Clin Lipidol. 2015 May-Jun; 9(3):377-83.
    View in: PubMed
    Score: 0.369
  6. Authors' reply. Am J Cardiol. 2013 Feb 01; 111(3):455-6.
    View in: PubMed
    Score: 0.325
  7. Long-term efficacy of adding fenofibric acid to moderate-dose statin therapy in patients with persistent elevated triglycerides. Cardiovasc Drugs Ther. 2011 Feb; 25(1):59-67.
    View in: PubMed
    Score: 0.283
  8. The evolving landscape of targets for lipid lowering: from molecular mechanisms to translational implications. Eur Heart J. 2025 Nov 21; 46(44):4737-4750.
    View in: PubMed
    Score: 0.197
  9. Epidemiology and longitudinal course of chylomicronemia: Insights from NHANES and a large health care system. J Clin Lipidol. 2025 May-Jun; 19(3):432-441.
    View in: PubMed
    Score: 0.189
  10. Effect of Targeting ApoC-III With Plozasiran on Lipoprotein Particle Size and?Number?in?Hypertriglyceridemia. J Am Coll Cardiol. 2025 May 20; 85(19):1839-1854.
    View in: PubMed
    Score: 0.188
  11. Zodasiran, an RNAi Therapeutic Targeting ANGPTL3, for Mixed Hyperlipidemia. N Engl J Med. 2024 09 12; 391(10):913-925.
    View in: PubMed
    Score: 0.178
  12. Olezarsen, Acute Pancreatitis, and Familial Chylomicronemia Syndrome. N Engl J Med. 2024 05 16; 390(19):1781-1792.
    View in: PubMed
    Score: 0.176
  13. RNA interference targeting ANGPTL3 for triglyceride and cholesterol lowering: phase 1 basket trial cohorts. Nat Med. 2023 09; 29(9):2216-2223.
    View in: PubMed
    Score: 0.169
  14. Combination therapy for combined dyslipidemia. Am J Cardiol. 2002 Nov 20; 90(10B):21K-29K.
    View in: PubMed
    Score: 0.160
  15. Genetic Testing for Hypertriglyceridemia in Academic Lipid Clinics: Implications for Precision Medicine-Brief Report. Arterioscler Thromb Vasc Biol. 2022 12; 42(12):1461-1467.
    View in: PubMed
    Score: 0.160
  16. Influence of low high-density lipoprotein cholesterol and elevated triglyceride on coronary heart disease events and response to simvastatin therapy in 4S. Circulation. 2001 Dec 18; 104(25):3046-51.
    View in: PubMed
    Score: 0.150
  17. Triglycerides and ASCVD Risk Reduction: Recent Insights and Future Directions. Curr Atheroscler Rep. 2020 06 03; 22(7):25.
    View in: PubMed
    Score: 0.135
  18. Reply: Ischemic Event Reduction and Triglycerides. J Am Coll Cardiol. 2019 10 08; 74(14):1849-1850.
    View in: PubMed
    Score: 0.129
  19. Reduction in First and Total Ischemic Events With Icosapent Ethyl Across Baseline Triglyceride Tertiles. J Am Coll Cardiol. 2019 08 27; 74(8):1159-1161.
    View in: PubMed
    Score: 0.128
  20. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. N Engl J Med. 2019 01 03; 380(1):11-22.
    View in: PubMed
    Score: 0.121
  21. Assessment of omega-3 carboxylic acids in statin-treated patients with high levels of triglycerides and low levels of high-density lipoprotein cholesterol: Rationale and design of the STRENGTH trial. Clin Cardiol. 2018 Oct; 41(10):1281-1288.
    View in: PubMed
    Score: 0.120
  22. Remnant-Like Particle Cholesterol, Low-Density Lipoprotein Triglycerides, and Incident Cardiovascular Disease. J Am Coll Cardiol. 2018 07 10; 72(2):156-169.
    View in: PubMed
    Score: 0.118
  23. Lipid Effects of Icosapent Ethyl in Women with Diabetes Mellitus and Persistent High Triglycerides on Statin Treatment: ANCHOR Trial Subanalysis. J Womens Health (Larchmt). 2018 09; 27(9):1170-1176.
    View in: PubMed
    Score: 0.116
  24. Usefulness of Icosapent Ethyl (Eicosapentaenoic Acid Ethyl Ester) in Women to Lower Triglyceride Levels (Results from the MARINE and ANCHOR Trials). Am J Cardiol. 2017 Feb 01; 119(3):397-403.
    View in: PubMed
    Score: 0.105
  25. Icosapent ethyl: Eicosapentaenoic acid concentration and triglyceride-lowering effects across clinical studies. Prostaglandins Other Lipid Mediat. 2016 09; 125:57-64.
    View in: PubMed
    Score: 0.103
  26. Icosapent ethyl (eicosapentaenoic acid ethyl ester): Effects on plasma apolipoprotein C-III levels in patients from the MARINE and ANCHOR studies. J Clin Lipidol. 2016 May-Jun; 10(3):635-645.e1.
    View in: PubMed
    Score: 0.100
  27. Loss-of-function mutations in APOC3, triglycerides, and coronary disease. N Engl J Med. 2014 Jul 03; 371(1):22-31.
    View in: PubMed
    Score: 0.089
  28. Rare LPL gene variants attenuate triglyceride reduction and HDL cholesterol increase in response to fenofibric acid therapy in individuals with mixed dyslipidemia. Atherosclerosis. 2014 Jun; 234(2):249-53.
    View in: PubMed
    Score: 0.088
  29. The editor's roundtable: hypertriglyceridemia. Am J Cardiol. 2013 Oct 15; 112(8):1133-41.
    View in: PubMed
    Score: 0.085
  30. APOE modulates the correlation between triglycerides, cholesterol, and CHD through pleiotropy, and gene-by-gene interactions. Genetics. 2013 Dec; 195(4):1397-405.
    View in: PubMed
    Score: 0.085
  31. Do genetic modifiers of high-density lipoprotein cholesterol and triglyceride levels also modify their response to a lifestyle intervention in the setting of obesity and type-2 diabetes mellitus?: The Action for Health in Diabetes (Look AHEAD) study. Circ Cardiovasc Genet. 2013 Aug; 6(4):391-9.
    View in: PubMed
    Score: 0.084
  32. Effects of icosapent ethyl on lipid and inflammatory parameters in patients with diabetes mellitus-2, residual elevated triglycerides (200-500 mg/dL), and on statin therapy at LDL-C goal: the ANCHOR study. Cardiovasc Diabetol. 2013 Jul 09; 12:100.
    View in: PubMed
    Score: 0.084
  33. Rare APOA5 promoter variants associated with paradoxical HDL cholesterol decrease in response to fenofibric acid therapy. J Lipid Res. 2013 Jul; 54(7):1980-7.
    View in: PubMed
    Score: 0.083
  34. Gene-centric meta-analysis of lipid traits in African, East Asian and Hispanic populations. PLoS One. 2012; 7(12):e50198.
    View in: PubMed
    Score: 0.080
  35. Icosapent ethyl, a pure EPA omega-3 fatty acid: effects on lipoprotein particle concentration and size in patients with very high triglyceride levels (the MARINE study). J Clin Lipidol. 2012 Nov-Dec; 6(6):565-72.
    View in: PubMed
    Score: 0.078
  36. LPL gene variants affect apoC-III response to combination therapy of statins and fenofibric acid in a randomized clinical trial of individuals with mixed dyslipidemia. J Lipid Res. 2012 Mar; 53(3):556-560.
    View in: PubMed
    Score: 0.075
  37. Barriers to non-HDL cholesterol goal attainment by providers. Am J Med. 2011 Sep; 124(9):876-80.e2.
    View in: PubMed
    Score: 0.074
  38. Variants in the APOA5 gene region and the response to combination therapy with statins and fenofibric acid in a randomized clinical trial of individuals with mixed dyslipidemia. Atherosclerosis. 2011 Dec; 219(2):737-42.
    View in: PubMed
    Score: 0.073
  39. Effects of combination therapy with rosuvastatin and fenofibric acid in patients with mixed dyslipidemia and high-sensitivity C-reactive protein (= 2 mg/L). cmb@bcm.tmc.edu. J Clin Lipidol. 2011 Sep-Oct; 5(5):401-7.
    View in: PubMed
    Score: 0.073
  40. Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. Circulation. 2011 May 24; 123(20):2292-333.
    View in: PubMed
    Score: 0.072
  41. Increased myocardial susceptibility to repetitive ischemia with high-fat diet-induced obesity. Obesity (Silver Spring). 2008 Dec; 16(12):2593-600.
    View in: PubMed
    Score: 0.060
  42. Familial chylomicronemia syndrome and treatments to target hepatic APOC3 mRNA. Atherosclerosis. 2025 04; 403:119114.
    View in: PubMed
    Score: 0.047
  43. Characteristics of US adults with the metabolic syndrome and therapeutic implications. Diabetes Obes Metab. 2004 Sep; 6(5):353-62.
    View in: PubMed
    Score: 0.045
  44. Adiponectin, inflammation, and the expression of the metabolic syndrome in obese individuals: the impact of rapid weight loss through caloric restriction. J Clin Endocrinol Metab. 2004 Jun; 89(6):2697-703.
    View in: PubMed
    Score: 0.045
  45. Icosapent ethyl following acute coronary syndrome: the REDUCE-IT trial. Eur Heart J. 2024 Apr 01; 45(13):1173-1176.
    View in: PubMed
    Score: 0.044
  46. Lipoprotein(a) Blood Levels and Cardiovascular Risk Reduction With Icosapent Ethyl. J Am Coll Cardiol. 2024 Apr 23; 83(16):1529-1539.
    View in: PubMed
    Score: 0.044
  47. Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Circulation. 2003 May 20; 107(19):2409-15.
    View in: PubMed
    Score: 0.041
  48. Evinacumab in severe hypertriglyceridemia with or without lipoprotein lipase pathway mutations: a phase 2 randomized trial. Nat Med. 2023 03; 29(3):729-737.
    View in: PubMed
    Score: 0.041
  49. Efficacy of rosuvastatin 10 mg in patients with the metabolic syndrome. Am J Cardiol. 2003 Mar 06; 91(5A):25C-27C; discussion 28C.
    View in: PubMed
    Score: 0.041
  50. Effects of sirolimus on plasma lipids, lipoprotein levels, and fatty acid metabolism in renal transplant patients. J Lipid Res. 2002 Aug; 43(8):1170-80.
    View in: PubMed
    Score: 0.039
  51. Effect of olezarsen targeting APOC-III on lipoprotein size and particle number measured by NMR in patients with hypertriglyceridemia. J Clin Lipidol. 2022 Sep-Oct; 16(5):617-625.
    View in: PubMed
    Score: 0.039
  52. Apolipoprotein C-III reduction in subjects with moderate hypertriglyceridaemia and at high cardiovascular risk. Eur Heart J. 2022 04 06; 43(14):1401-1412.
    View in: PubMed
    Score: 0.038
  53. Triglyceride-rich lipoproteins, apolipoprotein C-III, angiopoietin-like protein 3, and cardiovascular events in older adults: Atherosclerosis Risk in Communities (ARIC) study. Eur J Prev Cardiol. 2022 03 11; 29(2):e53-e64.
    View in: PubMed
    Score: 0.038
  54. Treatment With Icosapent Ethyl to Reduce Ischemic Events in Patients With Prior Percutaneous Coronary Intervention: Insights From REDUCE-IT PCI. J Am Heart Assoc. 2022 03 15; 11(6):e022937.
    View in: PubMed
    Score: 0.038
  55. A Head-to-Head Comparison of a Free Fatty Acid Formulation of Omega-3 Pentaenoic Acids Versus Icosapent Ethyl in Adults With Hypertriglyceridemia: The ENHANCE-IT Study. J Am Heart Assoc. 2022 03 15; 11(6):e024176.
    View in: PubMed
    Score: 0.038
  56. Correlation of non-high-density lipoprotein cholesterol with apolipoprotein B: effect of 5 hydroxymethylglutaryl coenzyme A reductase inhibitors on non-high-density lipoprotein cholesterol levels. Am J Cardiol. 2001 Aug 01; 88(3):265-9.
    View in: PubMed
    Score: 0.037
  57. Efficacy and tolerability of fluvastatin extended-release delivery system: a pooled analysis. Clin Ther. 2001 Feb; 23(2):177-92.
    View in: PubMed
    Score: 0.035
  58. Conventional and Novel Lipid Measures and Risk of Peripheral Artery Disease. Arterioscler Thromb Vasc Biol. 2021 03; 41(3):1229-1238.
    View in: PubMed
    Score: 0.035
  59. Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk: The STRENGTH Randomized Clinical Trial. JAMA. 2020 12 08; 324(22):2268-2280.
    View in: PubMed
    Score: 0.035
  60. Efficacy and safety of an extended-release formulation of fluvastatin for once-daily treatment of primary hypercholesterolemia. Am J Cardiol. 2000 Oct 01; 86(7):759-63.
    View in: PubMed
    Score: 0.035
  61. Multiancestry Genome-Wide Association Study of Lipid Levels Incorporating Gene-Alcohol Interactions. Am J Epidemiol. 2019 Jun 01; 188(6):1033-1054.
    View in: PubMed
    Score: 0.031
  62. Effect of moderate alcohol consumption on hypertriglyceridemia: a study in the fasting state. Arch Intern Med. 1999 May 10; 159(9):981-7.
    View in: PubMed
    Score: 0.031
  63. Correlation of serum triglyceride and its reduction by omega-3 fatty acids with lipid transfer activity and the neutral lipid compositions of high-density and low-density lipoproteins. Atherosclerosis. 1999 Apr; 143(2):285-97.
    View in: PubMed
    Score: 0.031
  64. Evaluation of the efficacy, safety and glycaemic effects of evolocumab (AMG 145) in hypercholesterolaemic patients stratified by glycaemic status and metabolic syndrome. Diabetes Obes Metab. 2017 01; 19(1):98-107.
    View in: PubMed
    Score: 0.026
  65. Lifestyle Intervention for Weight Loss and Cardiometabolic Changes in the Setting of Glucokinase Regulatory Protein Inhibition: Glucokinase Regulatory Protein-Leu446Pro Variant in Look AHEAD. Circ Cardiovasc Genet. 2016 Feb; 9(1):71-8.
    View in: PubMed
    Score: 0.025
  66. Influence of metabolic syndrome factors and insulin resistance on the efficacy of ezetimibe/simvastatin and atorvastatin in patients with metabolic syndrome and atherosclerotic coronary heart disease risk. Lipids Health Dis. 2015 Sep 04; 14:103.
    View in: PubMed
    Score: 0.024
  67. Inactivating mutations in NPC1L1 and protection from coronary heart disease. N Engl J Med. 2014 Nov 27; 371(22):2072-82.
    View in: PubMed
    Score: 0.023
  68. Low-density lipoprotein electronegativity is a novel cardiometabolic risk factor. PLoS One. 2014; 9(9):e107340.
    View in: PubMed
    Score: 0.023
  69. Effects of fenofibric acid on carotid intima-media thickness in patients with mixed dyslipidemia on atorvastatin therapy: randomized, placebo-controlled study (FIRST). Arterioscler Thromb Vasc Biol. 2014 Jun; 34(6):1298-306.
    View in: PubMed
    Score: 0.022
  70. The impact of rapid weight loss on oxidative stress markers and the expression of the metabolic syndrome in obese individuals. J Obes. 2013; 2013:729515.
    View in: PubMed
    Score: 0.022
  71. Elevated plasma SPARC levels are associated with insulin resistance, dyslipidemia, and inflammation in gestational diabetes mellitus. PLoS One. 2013; 8(12):e81615.
    View in: PubMed
    Score: 0.022
  72. Trans-ethnic fine-mapping of lipid loci identifies population-specific signals and allelic heterogeneity that increases the trait variance explained. PLoS Genet. 2013 Mar; 9(3):e1003379.
    View in: PubMed
    Score: 0.020
  73. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med. 2012 Nov 29; 367(22):2089-99.
    View in: PubMed
    Score: 0.020
  74. Large-scale gene-centric meta-analysis across 32 studies identifies multiple lipid loci. Am J Hum Genet. 2012 Nov 02; 91(5):823-38.
    View in: PubMed
    Score: 0.020
  75. Study design, rationale, and baseline characteristics: evaluation of fenofibric acid on carotid intima-media thickness in patients with type IIb dyslipidemia with residual risk in addition to atorvastatin therapy (FIRST) trial. Cardiovasc Drugs Ther. 2012 Aug; 26(4):349-58.
    View in: PubMed
    Score: 0.020
  76. Non-high-density lipoprotein cholesterol reporting and goal attainment in primary care. J Clin Lipidol. 2012 Nov-Dec; 6(6):545-52.
    View in: PubMed
    Score: 0.019
  77. Relation of lipid gene scores to longitudinal trends in lipid levels and incidence of abnormal lipid levels among individuals of European ancestry: the Atherosclerosis Risk in Communities (ARIC) study. Circ Cardiovasc Genet. 2012 Feb 01; 5(1):73-80.
    View in: PubMed
    Score: 0.019
  78. Combination of niacin and fenofibrate with lifestyle changes improves dyslipidemia and hypoadiponectinemia in HIV patients on antiretroviral therapy: results of "heart positive," a randomized, controlled trial. J Clin Endocrinol Metab. 2011 Jul; 96(7):2236-47.
    View in: PubMed
    Score: 0.018
  79. CD11c/CD18 expression is upregulated on blood monocytes during hypertriglyceridemia and enhances adhesion to vascular cell adhesion molecule-1. Arterioscler Thromb Vasc Biol. 2011 Jan; 31(1):160-6.
    View in: PubMed
    Score: 0.017
  80. Biological, clinical and population relevance of 95 loci for blood lipids. Nature. 2010 Aug 05; 466(7307):707-13.
    View in: PubMed
    Score: 0.017
  81. Marine omega-3 fatty acid intake: associations with cardiometabolic risk and response to weight loss intervention in the Look AHEAD (Action for Health in Diabetes) study. Diabetes Care. 2010 Jan; 33(1):197-9.
    View in: PubMed
    Score: 0.016
  82. Effects of cyclosporine therapy on plasma lipoprotein levels. JAMA. 1989 Jul 07; 262(1):53-6.
    View in: PubMed
    Score: 0.016
  83. Longitudinal impact of physical activity on lipid profiles in middle-aged adults: the Atherosclerosis Risk in Communities Study. J Lipid Res. 2009 Aug; 50(8):1685-91.
    View in: PubMed
    Score: 0.016
  84. Efficacy and safety of ABT-335 (fenofibric acid) in combination with atorvastatin in patients with mixed dyslipidemia. Am J Cardiol. 2009 Feb 15; 103(4):515-22.
    View in: PubMed
    Score: 0.015
  85. Efficacy and tolerability of fluvastatin XL 80 mg alone, ezetimibe alone, and the combination of fluvastatin XL 80 mg with ezetimibe in patients with a history of muscle-related side effects with other statins. Am J Cardiol. 2008 Feb 15; 101(4):490-6.
    View in: PubMed
    Score: 0.014
  86. Hyperlipidemia following heart transplantation: natural history and intervention with mevinolin (lovastatin). Transplant Proc. 1987 Aug; 19(4 Suppl 5):60-2.
    View in: PubMed
    Score: 0.014
  87. Meta-analysis of the cholesterol-lowering effect of ezetimibe added to ongoing statin therapy. Curr Med Res Opin. 2007 Aug; 23(8):2009-26.
    View in: PubMed
    Score: 0.014
  88. Low-density lipoprotein metabolism in cerebrotendinous xanthomatosis. Metabolism. 1987 Mar; 36(3):270-6.
    View in: PubMed
    Score: 0.013
  89. Leptin and incident type 2 diabetes: risk or protection? Diabetologia. 2006 Sep; 49(9):2086-96.
    View in: PubMed
    Score: 0.013
  90. A common PCSK9 haplotype, encompassing the E670G coding single nucleotide polymorphism, is a novel genetic marker for plasma low-density lipoprotein cholesterol levels and severity of coronary atherosclerosis. J Am Coll Cardiol. 2005 May 17; 45(10):1611-9.
    View in: PubMed
    Score: 0.012
  91. Relationship between low-density lipoprotein subclasses and asymptomatic atherosclerosis in subjects from the Atherosclerosis Risk in Communities (ARIC) Study. Biomarkers. 2004 Mar-Apr; 9(2):190-202.
    View in: PubMed
    Score: 0.011
  92. Effects of PPARalpha, gamma and delta haplotypes on plasma levels of lipids, severity and progression of coronary atherosclerosis and response to statin therapy in the lipoprotein coronary atherosclerosis study. Pharmacogenetics. 2004 Jan; 14(1):61-71.
    View in: PubMed
    Score: 0.011
  93. Comparative effects of simvastatin and atorvastatin in hypercholesterolemic patients with characteristics of metabolic syndrome. Clin Ther. 2003 Jun; 25(6):1670-86.
    View in: PubMed
    Score: 0.010
  94. Plasma lipid profile and incident ischemic stroke: the Atherosclerosis Risk in Communities (ARIC) study. Stroke. 2003 Mar; 34(3):623-31.
    View in: PubMed
    Score: 0.010
  95. Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: The Atherosclerosis Risk in Communities (ARIC) Study. Circulation. 2001 Sep 04; 104(10):1108-13.
    View in: PubMed
    Score: 0.009
  96. Achieving and maintaining National Cholesterol Education Program low-density lipoprotein cholesterol goals with five statins. Am J Med. 2001 Aug 15; 111(3):185-91.
    View in: PubMed
    Score: 0.009
  97. Degree of HLA mismatch as a predictor of death from allograft arteriopathy after heart transplant. Transplant Proc. 1993 Feb; 25(1 Pt 1):233-6.
    View in: PubMed
    Score: 0.005
  98. Lipoprotein(a) and apolipoprotein changes after cardiac transplantation. J Am Coll Cardiol. 1991 Oct; 18(4):926-30.
    View in: PubMed
    Score: 0.005
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.